Skip to main content
. Author manuscript; available in PMC: 2023 Apr 8.
Published in final edited form as: Science. 2022 Apr 8;376(6589):eabl5282. doi: 10.1126/science.abl5282

Figure 5. Cytotoxicity and specificity of engineered MAGE-A3-specific TCR.

Figure 5.

(A-B) Killing of A375 melanoma cell line by different MAGE-A3-specific TCR transduced human primary T cells.

(C-E) IFN-γ, TNF, and cytotoxic granule release (CD107a staining) by different MAGE-A3-specific TCR transduced human primary T cells, induced by the A375 melanoma cell line.

(F-G) Killing of HCT-116 colon cancer cell line by different MAGE-A3-specific TCR transduced human primary T cells.

(H-J) IFN-γ, TNF, and cytotoxic granule release (CD107a staining) by different MAGE-A3-specific TCR transduced human primary T cells, induced by the HCT-116 colon cancer cell line.

(K-M) Cytotoxic granule release (CD107a staining), TNF, and IFN-γ by different MAGE-A3-specific TCR transduced human primary T cells, induced by HLA-A1+ 293T cells pulsed with a titration of MAGE-3 peptide.

(N-P) Cytotoxic granule release (CD107a staining), TNF, and IFN-γ by different MAGE-A3-specific TCR transduced human primary T cells, induced by HLA-A1+ 293T cells pulsed with a titration of TITIN peptide.

(A-P) Data are representative of 3 independent experiments. Data are shown as mean ± SD of technical duplicates. ns: not significant; ✱: P<0.05; ✱✱: P<0.01; ✱✱✱: P<0.001; ✱✱✱✱: P<0.0001